BiotechTube

BBI503

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastrointestinal Stromal Tumors

Conditions

Gastrointestinal Stromal Tumors

Trial Timeline

Mar 13, 2017 → Jul 25, 2017

NCT ID
NCT02232620

About BBI503

BBI503 is a phase 2 stage product being developed by Sumitomo Pharma for Gastrointestinal Stromal Tumors. The current trial status is terminated. This product is registered under clinical trial identifier NCT02232620. Target conditions include Gastrointestinal Stromal Tumors.

What happened to similar drugs?

6 of 20 similar drugs in Gastrointestinal Stromal Tumors were approved

Approved (6) Terminated (4) Active (10)
🔄Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
✅Remimazolam TosilateJiangsu Hengrui MedicineApproved
❌Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3
🔄Esomeprazole IV + Omeprazole IVAstraZenecaPhase 3
🔄Durvalumab + FLOT chemotherapyAstraZenecaPhase 3
🔄EsomeprazoleAstraZenecaPhase 3
🔄EsomeprazoleAstraZenecaPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT02232620Phase 2Terminated
NCT02232646Phase 2Withdrawn
NCT02432690Phase 2Terminated
NCT02232633Phase 2Completed
NCT01781455Phase 1Completed

Competing Products

20 competing products in Gastrointestinal Stromal Tumors

See all competitors
ProductCompanyStageHype Score
Raludotatug Deruxtecan (R-DXd)Daiichi SankyoPhase 2
39
Patritumab deruxtecanDaiichi SankyoPhase 1/2
39
DS-6157aDaiichi SankyoPhase 1
21
DS-8201a + Physician's ChoiceDaiichi SankyoPhase 2
35
Naldemedine + PlaceboShionogiPhase 2
27
GemcitabineEli LillyPhase 1/2
32
OlaratumabEli LillyPhase 2
27
pemetrexed + cisplatinEli LillyPhase 2
35
cetuximabEli LillyPhase 2
35
BBI608 + Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Bevacizumab + Capecitabine + RegorafenibSumitomo PharmaPhase 1/2
32
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
40
Placebo + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol) + ICI35,868 (propofol)Johnson & JohnsonPhase 2
35
Remimazolam TosilateJiangsu Hengrui MedicineApproved
43
Famitinib capsules + Sunitinib CapsulesJiangsu Hengrui MedicinePhase 3
32
FamitinibJiangsu Hengrui MedicinePhase 2
31
Esomeprazole IV + Omeprazole IVAstraZenecaPhase 3
40
Durvalumab + FLOT chemotherapyAstraZenecaPhase 3
44
EsomeprazoleAstraZenecaPhase 3
40
AZD2171AstraZenecaPhase 2
35
EsomeprazoleAstraZenecaPhase 3
40